依決洛單抗 ，Edrecolomab，CAS:156586-89-9， AntibodySystem Laboratories

貨號：DHD17403

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75223.html

別名：17-1A, CAS: 156586-89-9

簡介：

Edrecolomab (Panorex) 是一種針對細胞表面糖蛋白 17-1A 的小鼠單克隆抗體，在上皮組織和腫瘤上表達。Edrecolomab 顯示出抗腫瘤活性，可用于結(jié)直腸癌的研究。

貨號：DHD17403

產(chǎn)品品牌：Antibodysystem

通用名：Edrecolomab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：17-1A

靶點;物種：Human CD326/EPCAM

種類：Mus musculus

受體鑒定：IgG2a-kappa

CAS: 156586-89-9

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻：

Edrecolomab (monoclonal antibody 17-1A). PMID: 9806108

Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. PMID: 11578913

Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. PMID: 29295696

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. PMID: 12241873

Technology evaluation: edrecolomab, Centocor Inc. PMID: 11249762

Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer. PMID: 11273586

Edrecolomab in the adjuvant treatment of colorectal carcinoma. PMID: 12517501

Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer. PMID: 12445374

Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. PMID: 15933417

When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab. PMID: 19273695

A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. PMID: 12743982

The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study. PMID: 15713997

Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. PMID: 15933423

Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. PMID: 10632331

Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells. PMID: 12176782

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. PMID: 21747085

A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer. PMID: 11182031

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. PMID: 19273708

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. PMID: 21044305

Marketed therapeutic antibodies compendium. PMID: 22531442

Immunomodulation therapy in colorectal carcinoma. PMID: 10814560

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. PMID: 29329202

Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition. PMID: 29667344

In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. PMID: 12115595

Recent developments in colorectal cancer treatment by monoclonal antibodies. PMID: 17049015

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. PMID: 17325709

EpCAM: A new therapeutic target for an old cancer antigen. PMID: 14508099

Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials. PMID: 29966444

Adjuvant therapy of colon cancer. PMID: 15726511

Antibody-targeted immunotherapy for treatment of malignancy. PMID: 11160771

Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. PMID: 20426706

[Adjuvant therapy for colon cancer]. PMID: 15497107

Monoclonal antibodies as therapeutic agents for cancer. PMID: 15120666

[Anti-cancer monoclonal antibody]. PMID: 15861718

Monoclonal antibodies in the treatment of colorectal cancer. PMID: 15177487

Monoclonal and bispecific antibodies as novel therapeutics. PMID: 16648969

Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer. PMID: 16955700

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). PMID: 27432924

Progress in colorectal cancer chemotherapy: how far have we come, how far to go? PMID: 11043819

Adjuvant therapy for colon cancer in the new millenium. PMID: 12705552

MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma. PMID: 12031098

Monoclonal antibodies in the treatment of cancer, Part 1. PMID: 12951753

EpCAM as a target in cancer therapy. PMID: 20385979

Expression of EpCAM in uveal melanoma. PMID: 17125516

Immunotherapy for colorectal cancer. PMID: 11122811

[Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review]. PMID: 21129296

EpCAM: a potential antimetastatic target for gastric cancer. PMID: 19941073

Current concepts in immunotherapy for the treatment of colorectal cancer. PMID: 12018689

Monoclonal antibodies in the treatment of cancer, Part 2. PMID: 12966906

Novel immunologic and biologic therapies for breast cancer. PMID: 11122896

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment. PMID: 21042730

[Clinical assessment of monoclonal antibodies for the treatment and diagnosis of colorectal cancers]. PMID: 11904970

Radiation and image distortion in the panorex x-ray unit. PMID: 14033188

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. PMID: 23530100

Letter to the editor: efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309-1. PMID: 20079406

Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. PMID: 21747089

Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody 17-1A and interleukin-2. PMID: 17562330

Yeast cell surface display system for determination of humoral response to active immunization with a monoclonal antibody against EpCAM. PMID: 18321588

[Development and use of anti-epithelial antibodies in solid tumors]. PMID: 11449629

Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target? PMID: 10655996

Expression of epithelial-cell adhesion molecule (Ep-CAM) in small cell lung cancer as defined by monoclonal antibodies 17-1A and BerEP4. PMID: 16227163

Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study. PMID: 12962368

Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A. PMID: 11031784

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. PMID: 10550551

Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. PMID: 15289873

Treatment of gastrointestinal tumors with MAb17-1A. PMID: 16312837

Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model. PMID: 14593230

Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2. PMID: 11350880

Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer. PMID: 11076666

Augmentation of 17-1A-induced antibody-dependent cellular cytotoxicity by the triple cytokine combination of interferon-alpha, interleukin-2, and interleukin-12. PMID: 10916758

Highlights from: 38th annual meeting of the American Society of Clinical Oncology. PMID: 12453319

25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000. PMID: 12445373